Jamie Sulivan - REDFILED (Page 2)

A wearable continuous glucose monitoring sensor worn on the upper arm.

ABT

FDA Authorizes First Dual Glucose and Ketone Wearable, Abbott's Libre Duo

The FDA cleared the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people with diabetes aged 2 and older.

Definitive Healthcare is a provider of healthcare market data and analytics.

DH

Advent Offers $1.02 a Share to Take Definitive Healthcare (DH) Private

A special committee of independent directors confirmed a non-binding all-cash proposal from Advent International for all shares it does not already own.

ABI

Abcourt Closes US$10M Debenture Upsize With Glencore, Repays Nebari Loan

Abcourt Mines lifted its Glencore senior secured debenture to US$40 million, drew US$19.875 million and repaid a US$12 million Nebari credit facility.

Borealis Foods, the maker of Chef Woo noodles, is listed on the Nasdaq Capital Market.

BRLS

Borealis Foods Gets Nasdaq Deficiency Notice Over Late Q2 10-Q

Borealis Foods says a review of the accounting treatment of its Conversion Agreement delayed its second-quarter report, triggering a Nasdaq compliance notice.

Clinical

Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC

The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.

HRMY

Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X

The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026.

Clinical

PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer

PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.

VRT

Vertiv Signs $1.45 Billion Merger Deal for Utility Innovation Holdings

Vertiv Corporation agreed to acquire Utility Innovation Holdings via merger, with a base purchase price of $1.45 billion plus an earnout, per an 8-K filing.

INCY

Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed

The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.